As a mage, I just want to pursue the truth

Chapter 22 The Flock of Investment Institutions

"I have basic trust in you, and I also believe in your ethics as a professional manager, but if the company is all owned by Mr. Lei, then even if I own 90.00% of the shares in this company, it is not my company."

"I believe you can understand what I mean. I prefer to prepare in advance. The relationship between seniors and juniors is not guaranteed. You should know how big the endorphin market is."

Zheng Li did not shy away from his purpose and his worries about Cheng Gang and the people sent by Lei Jun.

After saying this, Cheng Gang's evaluation of Zheng Li was even higher. Everything can be done if it is forewarned, and if it is not forewarned, it will be abandoned.

As a young man, it is very difficult to keep a clear mind when getting 5000 million investment from the other party.

In addition, Cheng Gang is also very curious about Li Miaomiao, what is so special about Li Miaomiao that she can entrust Zheng Li with a heavy responsibility.

"I understand your concerns. I will prove my integrity with actions. As long as I am still in Science and Technology, I will consider its interests."

"In addition, Ms. Li, I am crazy about how old you are, and I usually call you Miao Miao, do you think it's okay?"

Li Miaomiao replied: "No problem, Brother Cheng."

Cheng Gang secretly thought that the other party was also a wonderful person, and he could understand his subtext immediately:
"Miaomiao, let me give you a general introduction to our company's structure. For the time being, there are only the financial department, human resources department, legal department and R&D department, because our first product has not yet been officially launched."

"On the eve of our first drug being approved for marketing, we will set up a sales department to be responsible for the sales of the drug. The structure of a start-up biopharmaceutical company is roughly the same: finance, human resources, sales, legal affairs and R&D."

"Public relations, clinical trials, quality management, etc., will only be considered after the company grows."

"In the future, we will have our own first-line standardized production base."

"Like Hengrui Medicine, they have their own production bases in many places across the country, and they also have a research and development production base in Gusu."

"In our company, Mr. Zheng is in charge of the R&D department, and I am in charge of other departments, but Mr. Zheng has the right to make decisions."

"My personal suggestion to you is that you mainly participate in the work of personnel and finance in the early stage, so that you can have a grasp of the overall situation of the company as soon as possible."

“Once you get your hands on finance and HR, then dig deeper into the business.”

After Cheng Gang finished speaking, Zheng Li nodded slightly. He knew that Cheng Gang's proposal had no selfish motives of his own.

Li Miaomiao: "Thank you Brother Cheng for your opinion, I also think it's better to start with personnel and finance."

Zheng Li made a final decision: "Then Cheng Gang, you make arrangements, and I will continue to work downstairs."

Before a new drug is put into formal clinical trials, qualitative analysis and preclinical trials are required, and then it must be approved by the State Food and Drug Administration before it can conduct human clinical trials.

The qualitative analysis of endorphins is relatively simple, because there are previous papers for qualitative analysis, Kechuangbiology only needs to write a review.

Preclinical trials are relatively more difficult, because before the patent registration is approved, endorphins cannot be mass-produced industrially and can only be prepared by laboratory methods.

After one and a half months, Kechuang Biology completed the preclinical test work and entered the period of waiting for the approval of clinical trials.

Endorphin is very special. It is not a completely new drug. It was discovered very early, but it is not a generic drug, because no pharmaceutical company has mass-produced endorphin for sale before.

If it is a generic drug, clinical trials are not required, only bioequivalence trials are required.

Domestic biomedical patent registration is faster than ordinary patent registration, and endorphin is an innovative drug, so the registration process is even faster.

After three months, the industrialized production method of orphin has been approved by the national patent, and the results of the first phase of clinical trials have also come out.

Generally, only 20 to 80 cases are needed for the first phase of clinical trials, and 100 cases were used for the first phase of clinical trials of endorphin.

Phase I clinical trial verified the efficacy of endorphin injection, proving that its analgesic effect is better than that of morphine, among which, in the controlled experiment, it was proved that endorphin is still effective for some patients who are resistant to analgesics. works.

At the same time, the worldwide patent registration of endorphin is coming to an end.

This also led to Lei Jun's first investment of 5000 million yuan, which was not much left, and Kechuang Biology was about to start the second round of investment.

In fact, as early as after the patent was approved, relevant investment institutions had approached Cheng Gang and asked for a door-to-door investigation.

As soon as the first-phase clinical trial report came out, many institutions with great powers had already obtained it.

Investment institutions all believe that this is a business that can make money without losing money, and if you invest, you will make money.

At the same time, these investment institutions once again raised their evaluation of Zheng Li.

There is an insurmountable gap between laboratory products and industrial production, and many laboratory products are many years away from commercial use.

Zheng Li was able to invent a laboratory method for making endorphins, and simplified the process to achieve industrialized mass production. Investment institutions also invest in science and technology innovation for people.

All of a sudden, investment institutions poured in.

"Stephanie, you also know that I'm just the general manager, and I can't get in on the second round of investment in Kechuang Bio."

Cheng Gang looked helpless. The recent phone calls took up a lot of his energy, because many of them were acquaintances who couldn't refuse.

Investment institutions came to harass Zheng Li if they couldn't reach him. Now he is talking to Stephanie Hui, the head of the Greater China investment department of Goldman Sachs Group.

"We are really optimistic about the prospects of Kechuang Bio, and hope to participate in the second round of investment of Kechuang Bio."

"Goldman Sachs can help Kechuang Bio to speed up the progress of European and American patent applications, and can help you complete clinical trials faster and obtain FDA approval."

"Goldman Sachs can help the growth of science and technology in all aspects."

The conditions proposed by Stephanie are all urgently needed by science and technology innovation.

Cheng Gang was unmoved. He smiled wryly and said, "Stephanie, what you said, I have heard IDG's Young, Sequoia's Tuvia, Hillhouse's George, etc. tell me about it."

"I am very moved by what you said. I am willing to let you participate in the second round of venture capital, but I am not a big boss. I don't even have any shares. I am just a manager."

"When the second round of investment will start, when to invest, and which institutions to participate in, I have no right to decide."

"Ask Mr. Lei of Dami, he has more authority than me."

Stephanie smiled and said, "It seems that I'm bothering you. I don't need you to give me a positive answer, and I don't need you to do anything against the interests of your company."

"I just want to meet Mr. Zheng, and I hope to have afternoon tea with him, and it is best to have lunch with him."

(End of this chapter)